
Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding ...
On Monday, Nanobiotix SA NBTX announced an amendment to its global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company JNJ, as part of its financial strategy. The revision relieves Nanobiotix of funding obligations for its …